Scott joined Oxford Science Enterprises in June 2024, bringing nearly 20 years of experience in developing gene therapies from both small biotech and large pharmaceutical companies.
At OSE, Scott focuses on identifying and evaluating new opportunities, forming new spinouts, and supporting the growth of the Life Sciences portfolio.
Before joining OSE, Scott was Executive Director of Ophthalmology at Novartis, following its acquisition of Gyroscope Therapeutics for up to $1.5 billion. At Gyroscope, he served as SVP of Preclinical Research, leading the AAV pipeline and platform development. Prior to that, Scott spent over a decade at Oxford Biomedica, a lentiviral vector gene therapy company, where he was Head of Early Development. Over his career, he has advanced multiple gene therapy pipeline and platform programs, both internally and through strategic collaborations, from concept to Phase 2 clinical trials.
Scott holds a PhD in Retrovirology and Mouse Genetics from University College London and a degree in Applied Biology from the University of Bath.
